A carregar...
Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment
Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit from regorafenib treatment. Metastatic colore...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7649869/ https://ncbi.nlm.nih.gov/pubmed/33224274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920965842 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|